XYZAL

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Cyprus, Estonia, Finland, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Malta, Netherlands, Nigeria, Poland, Romania, Singapore, South Africa, UK.

Active ingredients

The drug XYZAL contains one active pharmaceutical ingredient (API):

1	Levocetirizine UNII SOD6A38AGA - LEVOCETIRIZINE DIHYDROCHLORIDE
	Levocetirizine, the ® enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.
	Read more about Levocetirizine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XYZAL Oral solution	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AE09	Levocetirizine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AE Piperazine derivatives
Discover more medicines within R06AE09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1138126, 1138137, 1148521, 1148532, 1148543, 1148554, 1148565, 1148587, 1148598, 1148600, 1148611, 1148622, 1148633, 1148644, 1148655, 1148666, 1148677, 1148688, 1223064
FI	Lääkealan turvallisuus- ja kehittämiskeskus	007908, 008641, 059406, 150194, 165240
GB	Medicines & Healthcare Products Regulatory Agency	117602, 36036
HK	Department of Health Drug Office	49629, 54600
HR	Agencija za lijekove i medicinske proizvode	HR-H-232981652
IE	Health Products Regulatory Authority	53968, 53974, 74700, 74725, 74732, 74770
IT	Agenzia del Farmaco	035666080
JP	医薬品医療機器総合機構	4490028F1027, 4490028Q1028
LT	Valstybinė vaistų kontrolės tarnyba	1019998, 1019999, 1020000, 1020001, 1020002, 1020005, 1020006, 1020007, 1020008, 1020009, 1020010, 1020011, 1020012, 1020013, 1020014, 1020015, 1020016, 1021389, 1022346, 1069326, 1082388
MT	Medicines Authority	MA030/00701, MA030/00702
NG	Registered Drug Product Database	A4-6915
Switch country to Nigeria in order to find specific presentations of XYZAL
NL	Z-Index G-Standaard, PRK	60976, 81698
PL	Rejestru Produktów Leczniczych	100147912, 100163510, 100399068, 100407336
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W58148001, W58148002, W58148003, W65372001, W65372002, W65372003, W65372005, W65372006, W65372007, W65372008, W65372009, W65372010, W65372011, W65372012, W65372013, W65372014, W65372015, W65372016, W65372017
SG	Health Sciences Authority	12084P, 13469P, 13470P
US	FDA, National Drug Code	0024-5803, 0024-5804
ZA	Health Products Regulatory Authority	36/5.7.1/0425, 41/5.7.1/0032